English
Structure via PubChem · Public domain (PubChem)
lesogaberan
Sign in to saveAlso known as AZD3355
Lesogaberan (AZD-3355) was an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD). As a GABAB receptor agonist, it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.
Chemical data
- Formula
- C3H9FNO2P
- Molecular weight
- 141.08 g/mol
- IUPAC name
- [(2R)-3-amino-2-fluoropropyl]phosphinic acid
- SMILES
- C([C@H](CP(=O)O)F)N
- InChIKey
- LJNUIEQATDYXJH-GSVOUGTGSA-N
- XLogP
- -3.9
- Polar surface area
- 63.3 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- gastroesophageal reflux disease
via ChEMBL · EBI
Research
36 papers- Reducing Adverse Effects During Drug Development: The Example of Lesogaberan and Paresthesia.Clinical therapeutics · 2016
- Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'.Current opinion in pharmacology · 2011
- Repurposing Lesogaberan to Promote Human Islet Cell Survival and β-Cell Replication.Journal of diabetes research · 2017
- Inhibition of transient lower esophageal sphincter relaxation in GERD: will lesogaberan advance the field?Gastroenterology · 2010
- Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis.EClinicalMedicine · 2023
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 141.035493378
Show 3 more facts
- canonical SMILES
- C(C(CP(=O)O)F)N
- isomeric SMILES
- C([C@H](CP(=O)O)F)N
- chemical formula
- C₃H₉FNO₂P
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Lesogaberan (AZD-3355) was an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD). As a GABAB receptor agonist, it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.
==References==
Excerpted from Wikipedia’s “lesogaberan” article, available under the CC BY-SA 4.0 licence.